| Description | Polymyxin B, an antibiotic, combats Gram-negative infections through high-affinity binding to the bacterial wall's lipopolysaccharides (LPS), neutralizing endotoxin effects and inducing bacterial cell death by enhancing permeability. It is utilized in endotoxemia research [1] [3]. |
| In vitro | 波利默霉素B（10 μg/mL，6小时）抑制了人类外周血单核细胞（PBMC）产生的TNF-α 和 IL-10 [3]。 |
| In vivo | Polymyxin B（5-20 mg/kg，静脉注射；每日1次，连续7天）在20 mg/kg剂量下导致Sprague-Dawley大鼠模型出现肾毒性，而5 mg/kg剂量未见此效应[2]。 |
| molecular weight | N/A |
| CAS | 1404-26-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Martin EL, et al. Endotoxin removal: how far from the evidence? The EUPHAS 2 Project. Contrib Nephrol. 2010;167:119-125. 2. Cardoso LS, et al. Polymyxin B as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in human cytokine analysis. Microb Cell Fact. 2007 Jan 3;6:1. |
| Citations | 1. Cui R, Zhang J, Liu X, et al.Dronedarone Enhances the Antibacterial Activity of Polymyxin B and Inhibits the Quorum Sensing System by Interacting with LuxS.ACS Infectious Diseases.2024 |